… Primary patency of VIA (red) versus BMS (black) in SFA lesions of patients with symptomatic
PAD and lesions ≥20 cm at 24 months (TPP): VIA 65.2 (95 % CI 0.50–0.85) versus BMS …

… PACT SFA randomized trial demonstrated that, for lesions in the SFA and proximal popliteal
… -term results from this trial demonstrates a sustained benefit of DCB over PTA at 24 months. …

… a sustained treatment effect with superior freedom from clinically driven target lesion …
long-term benefit with regard to avoidance of target lesion revascularization that persists for …

… of clinical and angiographic benefit of PCBs, especially for … the SFA-Long (Drug Eluting
Balloon [DEB] and Long Lesions … for all de novo lesions of the SFA in routine clinical practice. …

… However, the inherent benefits of such permanent prostheses over PTA alone have not
convinced all operators to use them in a routine fashion, especially for long lesions for which …

… PTA + BMS in complex FPA lesions, reduces restenosis and target lesion revascularization
at 12-month follow-up. Restenosis reduction is maintained irrespective of lesion length and …

… This concept is currently investigated in the DEFINITIVE AR study randomizing 100 patients
with calcified SFA lesions either to DCb only or atherectomy followed by local drug delivery …

… lesion length in the DCB arm of the IN.PACT SFA trial was at the upper margin of lesion …
The results of this analysis show sustained clinical benefit up to 3 years after treatment with a …

… SFA Registry assesses safety, clinical benefit, and outcomes of the Lutonix 035 DCB in
femoropopliteal lesions … femoropopliteal lesions, challenging comorbidities, and difficult lesions. …

… Both treatment strategies conferred a meaningful and sustained … the SFA after PTA could
not be recommended, although the authors did note that there was a small, short-term benefit of …